Erratum: Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: A sub-analysis of a pharmacokinetics/phar-macodynamics study [Clinical Nephrology, 84, 1 (2015) (29-38) DOI: 10.5414/CN108457;Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: A sub-analysis of a pharmacokinetics/pharmacodynamics study

Clinical Nephrology

Volumn 84, Issue 1, 2015, Pages 29-38

  Tominaga, Naoto ^a   Kida, Keisuke ^a   Matsumoto, Naoki ^a   Akashi, Yoshihiro J ^a   Miyake, Fumihiko ^a   Kimura, Kenjiro ^a   Shibagaki, Yugo ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic kidney disease; Congestive heart failure; Furosemide; Tolvaptan; Vasopressin V2 receptor antagonist

Indexed keywords

CREATININE; FUROSEMIDE; POTASSIUM; SODIUM; TOLVAPTAN; UREA; URIC ACID; BENZAZEPINE DERIVATIVE; DIURETIC AGENT; VASOPRESSIN RECEPTOR ANTAGONIST;

ACID BASE BALANCE; ADD ON THERAPY; ADULT; ADVANCED CHRONIC KIDNEY DISEASE; AGED; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; BODY FLUID; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEMALE; FORWARD HEART FAILURE; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART RATE; HEMODYNAMIC PARAMETERS; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERNATREMIA; HYPOKALEMIA; KIDNEY FUNCTION; MALE; NITROGEN METABOLISM; PHARMACODYNAMICS; PILOT STUDY; PLEURA EFFUSION; POTASSIUM BLOOD LEVEL; SODIUM BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINE VOLUME; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; DRUG INTERACTION; HEART FAILURE; METABOLISM; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; BLOOD PRESSURE; BLOOD UREA NITROGEN; CREATININE; DIURETICS; DRUG INTERACTIONS; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RENAL INSUFFICIENCY, CHRONIC; URIC ACID;

EID: 84934754598     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP87220     Document Type: Erratum

References (24)

1. Greenberg A. Diuretic complications. Am J Med Sci. 2000; 319: 10-24.
2. Wilcox CS. Metabolic and adverse effects of diuretics. Semin Nephrol. 1999; 19: 557-568.
3. Sarafidis PA, Georgianos PI, Lasaridis AN. Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy. Expert Opin Drug Saf. 2010; 9: 259-273.
4. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998; 287: 860-867.
5. Elhassan EA, Schrier RW. Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists. Curr Opin Nephrol Hypertens. 2011; 20: 161-168.
6. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS; SALT Investigators. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol. 2011; 164: 725-732.
7. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006; 290: F273-F278.
8. Matsuzaki M, Hori M, Izumi T, Fukunami M; Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011; 25 (Suppl 1): S33-S45.
9. The Criteria Committee for the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels Ninth Edition. Little Brown and Company. 1994. 253-255.
10. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982-992.
11. Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP; EVEREST investigators. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med (Hagerstown). 2012; 13: 415-422.
12. Mori T, Oba I, Koizumi K, Kodama M, Shimanuki M, Tanno M, Chida M, Saito M, Kiyomoto H, Miyazaki M, Ogawa S, Sato H, Ito S. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis. Adv Perit Dial. 2013; 29: 33-37.
13. Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol. 2013; 17: 834-838.
14. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010; 56: 1527-1534.
15. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008; 10: 188-195.
16. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43: 61-67.
17. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B; POSH Investigators. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J. 2006; 27: 1216-1222.
18. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated metaanalysis. Eur Heart J. 2014; 35: 455-469.
19. Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J. 2010; 160: 264-271.e1.
20. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004; 147: 331-338.
21. Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011; 25 (Suppl 1): S67-S76.
22. Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, Giammanco M, Sarullo FM, Licata G. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol. 2005; 45: 1997-2003.
23. Ribiero A, Mulinasi R, Gavras I, et al. Sequential elimination of pressor mechanisms in severe hypertension in humans. Hypertension. 1986; 8 (Suppl I): 169-173.
24. Jutabha P, Anzai N, Wempe MF, Wakui S, Endou H, Sakurai H. Apical voltage-driven urate efflux transporter NPT4 in renal proximal tubule. Nucleosides Nucleotides Nucleic Acids. 2011; 30: 1302-1311.